| Browse All

Psyence Biomedical Ltd. (PBMWW)

Toronto, Canada | NasdaqCM
0.05 USD +0.05 (0.000%) ⇧ (April 20, 2026, 3:59 p.m. EDT)

Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 12:47 a.m. EDT

Psyence Biomedical Ltd. (PBMWW) presents a classic value trap with deteriorating fundamentals: negative ROE/-40% ROA, bleeding cash flows, and a stagnant price action at 52-week lows with zero momentum. Combined with virtually no dividend yield and no analyst coverage, the risk/reward profile is strongly bearish for both short-term trades and long-term holds.

None
Attribute Value
Beta 0.31
Previous Name Psyence Therapeutics Corp.
Website https://www.psyencebiomed.com

Info Dump

Attribute Value
Address1 121 Richmond Street West
Address2 Penthouse Suite, 1300
Ask 0.0
Ask Size 0
Beta 0.306
Bid 0.0
Bid Size 0
Book Value 39.619
City Toronto
Compensation As Of Epoch Date 1,767,139,200
Country Canada
Crypto Tradeable 0
Currency USD
Current Price 0.045
Current Ratio 8.09
Custom Price Alert Confidence HIGH
Day High 0.06
Day Low 0.0344
Display Name Psyence Biomedical
Ebitda -4,145,455
Ebitda Margins 0.0
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Two Week High 0.06
Fifty Two Week High Change -0.014999997
Fifty Two Week High Change Percent -0.24999996
Fifty Two Week Low 0.0344
Fifty Two Week Low Change 0.010600001
Fifty Two Week Low Change Percent 0.30813953
Fifty Two Week Range 0.0344 - 0.06
Financial Currency USD
First Trade Date Milliseconds 1,772,807,400,000
Float Shares 292,594
Free Cashflow -4,006,023
Full Exchange Name NasdaqCM
Full Time Employees 12
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Industry
Industry Key
Ipo Expected Date 2,024-01-26
Language en-US
Long Business Summary Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Long Name Psyence Biomedical Ltd.
Market us_market
Market State PRE
Max Age 86,400
Message Board Id finmb_698500412
Name Change Date 2,026-04-20
Net Income To Common -3,941,597
Open 0.024
Operating Cashflow -4,247,508
Operating Margins 0.0
Phone 416 346 7764
Prev Name Psyence Therapeutics Corp.
Previous Close 0.0
Price Hint 4
Price To Book 0.0011358188
Profit Margins 0.0
Quick Ratio 7.766
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.045
Regular Market Change Percent 0.0
Regular Market Day High 0.06
Regular Market Day Low 0.0344
Regular Market Day Range 0.0344 - 0.06
Regular Market Open 0.024
Regular Market Previous Close 0.0
Regular Market Price 0.045
Regular Market Time 1,776,715,190
Regular Market Volume 1,775,298
Return On Assets -0.34442002
Return On Equity -0.74286
Sand P52 Week Change 0.34445214
Sector
Sector Key
Short Name Psyence Biomedical Ltd. Warrant
Source Interval 15
State ON
Symbol PBMWW
Total Cash 7,149,985
Total Cash Per Share 23.871
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield NaN
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 1,775,298
Website https://www.psyencebiomed.com
Zip M5H2K1